View ValuationSunrest Lifescience 将来の成長Future 基準チェック /06現在、 Sunrest Lifescienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長16.6%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 01Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million.Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 4,291,200 Price\Range: INR 35 Transaction Features: Regulation S; Rights OfferingValuation Update With 7 Day Price Move • Mar 23Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹40.00, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 32% over the past year.Buy Or Sell Opportunity • Mar 16Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₹48.00. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Buy Or Sell Opportunity • Feb 18Now 21% overvaluedOver the last 90 days, the stock has fallen 6.2% to ₹43.80. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only.Valuation Update With 7 Day Price Move • Jan 12Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹35.05, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.Board Change • Dec 29Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Nov 12Sunrest Lifescience Limited to Report First Half, 2026 Results on Nov 13, 2025Sunrest Lifescience Limited announced that they will report first half, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total loss to shareholders of 18% over the past year.お知らせ • Sep 03Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025, at 15:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹61.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total loss to shareholders of 4.0% over the past year.New Risk • Jun 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Shares are highly illiquid. Market cap is less than US$10m (₹214.8m market cap, or US$2.51m). Minor Risk Revenue is less than US$5m (₹334m revenue, or US$3.9m).New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹218.9m market cap, or US$2.56m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Revenue is less than US$5m (₹324m revenue, or US$3.8m).お知らせ • Dec 19Sunrest Lifescience Limited Announces Resignation of Nishi Shah as Company Secretary & Compliance OfficerSunrest Lifescience Limited announced that Ms. Nishi Shah has tendered her resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide his letter dated 17th December, 2024. She has decided to move on to pursue opportunities outside the Company.New Risk • Nov 16New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹236.2m market cap, or US$2.80m). Minor Risk Revenue is less than US$5m (₹324m revenue, or US$3.8m).お知らせ • Sep 14Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024, at 15:00 Indian Standard Time.Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹0.68 (vs ₹6.81 in FY 2023)Full year 2024 results: EPS: ₹0.68 (down from ₹6.81 in FY 2023). Revenue: ₹294.8m (up 20% from FY 2023). Net income: ₹2.26m (down 89% from FY 2023). Profit margin: 0.8% (down from 8.3% in FY 2023). The decrease in margin was driven by higher expenses.Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹75.00, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.New Risk • May 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹317.5m market cap, or US$3.80m). Minor Risks High level of debt (54% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (₹246m revenue, or US$3.0m).New Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹301.5m market cap, or US$3.62m). Minor Risks High level of debt (54% net debt to equity). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹246m revenue, or US$3.0m).Board Change • Nov 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Sunrest Lifescience は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測NSEI:SUNREST - アナリストの将来予測と過去の財務データ ( )INR Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/202552018-2732N/A6/30/202542719-630N/A3/31/2025334201529N/A12/31/20243294-51-44N/A9/30/2024324-12-118-118N/A6/30/2024315-2-133-133N/A3/31/20242952-148-148N/A12/31/20232788-72-72N/A3/31/2023246201112N/A3/31/20222698-9-4N/A3/31/2021169202N/A3/31/20201100-9-9N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: SUNRESTの予測収益成長が 貯蓄率 ( 6.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SUNRESTの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SUNRESTの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SUNRESTの収益がIndian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SUNRESTの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SUNRESTの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 08:54終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sunrest Lifescience Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 01Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million.Sunrest Lifescience Limited has withdrawn its Follow-on Equity Offering in the amount of INR 150.192 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 4,291,200 Price\Range: INR 35 Transaction Features: Regulation S; Rights Offering
Valuation Update With 7 Day Price Move • Mar 23Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹40.00, the stock trades at a trailing P/E ratio of 9.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total loss to shareholders of 32% over the past year.
Buy Or Sell Opportunity • Mar 16Now 32% overvalued after recent price riseOver the last 90 days, the stock has risen 12% to ₹48.00. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Buy Or Sell Opportunity • Feb 18Now 21% overvaluedOver the last 90 days, the stock has fallen 6.2% to ₹43.80. The fair value is estimated to be ₹36.25, however this is not to be taken as a sell recommendation but rather should be used as a guide only.
Valuation Update With 7 Day Price Move • Jan 12Investor sentiment deteriorates as stock falls 22%After last week's 22% share price decline to ₹35.05, the stock trades at a trailing P/E ratio of 8.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total loss to shareholders of 34% over the past year.
Board Change • Dec 29Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 12Sunrest Lifescience Limited to Report First Half, 2026 Results on Nov 13, 2025Sunrest Lifescience Limited announced that they will report first half, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹49.00, the stock trades at a trailing P/E ratio of 10.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total loss to shareholders of 18% over the past year.
お知らせ • Sep 03Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025Sunrest Lifescience Limited, Annual General Meeting, Sep 27, 2025, at 15:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jun 18Investor sentiment improves as stock rises 22%After last week's 22% share price gain to ₹61.00, the stock trades at a trailing P/E ratio of 13.1x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total loss to shareholders of 4.0% over the past year.
New Risk • Jun 03New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 12% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (12% operating cash flow to total debt). Shares are highly illiquid. Market cap is less than US$10m (₹214.8m market cap, or US$2.51m). Minor Risk Revenue is less than US$5m (₹334m revenue, or US$3.9m).
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹218.9m market cap, or US$2.56m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Revenue is less than US$5m (₹324m revenue, or US$3.8m).
お知らせ • Dec 19Sunrest Lifescience Limited Announces Resignation of Nishi Shah as Company Secretary & Compliance OfficerSunrest Lifescience Limited announced that Ms. Nishi Shah has tendered her resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide his letter dated 17th December, 2024. She has decided to move on to pursue opportunities outside the Company.
New Risk • Nov 16New major risk - Revenue and earnings growthEarnings have declined by 15% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 15% per year over the past 5 years. Market cap is less than US$10m (₹236.2m market cap, or US$2.80m). Minor Risk Revenue is less than US$5m (₹324m revenue, or US$3.8m).
お知らせ • Sep 14Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024Sunrest Lifescience Limited, Annual General Meeting, Sep 28, 2024, at 15:00 Indian Standard Time.
Reported Earnings • May 29Full year 2024 earnings released: EPS: ₹0.68 (vs ₹6.81 in FY 2023)Full year 2024 results: EPS: ₹0.68 (down from ₹6.81 in FY 2023). Revenue: ₹294.8m (up 20% from FY 2023). Net income: ₹2.26m (down 89% from FY 2023). Profit margin: 0.8% (down from 8.3% in FY 2023). The decrease in margin was driven by higher expenses.
Valuation Update With 7 Day Price Move • May 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ₹75.00, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 34x in the Pharmaceuticals industry in India.
New Risk • May 15New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.7% average weekly change). Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹317.5m market cap, or US$3.80m). Minor Risks High level of debt (54% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Revenue is less than US$5m (₹246m revenue, or US$3.0m).
New Risk • May 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 8.4% over the past year. High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹301.5m market cap, or US$3.62m). Minor Risks High level of debt (54% net debt to equity). Share price has been volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$5m (₹246m revenue, or US$3.0m).
Board Change • Nov 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Independent Director Avani Shah was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.